Revvity Cxcl9/Mig (H) Lance Ultr

Revvity The LANCE Ultra Human CXCL9/MIG Detection Kit is designed for detection and quantitation of human CXCL9/MIG in cell culture media using a homogeneous TR-FRET (no-wash steps, no separation steps) assay. - REVPFZ (Additional S&H Or Hazmat Fees May Apply)

Revvity The 500 point kit contains enough reagents to run 500 wells in 384-well format, using a 20 µL reaction volume (15 µL of sample). The 10,000 point kit contains enough reagents to run 10,000 wells in 384-well format, using a 20 µL reaction volume (15 µL of sample). - REVPFZ (Additional S&H Or Hazmat Fees May Apply)

No-wash steps, no separation stepsTR-FRET technologySensitive detectionHigh reproducibilityFaster time-to-resultsEasy automation96-well, 384-well, and 1536-well formats

Revvity LANCE and LANCE (Lanthanide chelate excite) Ultra are our TR-FRET (time-resolved fluorescence resonance energy transfer), homogeneous (no wash) technologies. One antibody of interest is labeled with a donor fluorophore (a LANCE Europium chelate) and the second molecule is labeled with an acceptor fluorophore (ULight^™ dye). Upon excitation at 320 or 340 nm, energy can be transferred from the donor Europium chelate to the acceptor fluorophore if sufficiently close for FRET (~10 nm). This results in the emission of light at 665 nm. - REVPFZ (Additional S&H Or Hazmat Fees May Apply)

Revvity C-X-C Motif Chemokine 9 (CXCL9), previously called MIG, is a 14 kDa protein belonging to the intercrine alpha (chemokine CXC) family. Its induction is enhanced by TNFα in dermal fibroblasts and vein endothelial cells. The synthesis of CXCL9 is specifically induced in macrophages, monocytes, neutrophils, APC, B cells, and eosinophils by IFNγ and mediated via the JAK-STAT signaling pathway. The main function of this chemokine is the recruitment of leukocytes to sites of infection and inflammation. Some studies have shown that CXCL9 is active against Gram-negative and Gram-positive bacteria. CXCL9 may play a role as a mediator of T-cell recruitment and activation in some diseases like psoriasis and pulmonary disease. CXCL9 is expressed in allogeneic skin grafts several days before completion of rejection. - REVPFZ (Additional S&H Or Hazmat Fees May Apply)